Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (341-350 of 377) with videos related to

Pageof 38
Sort By:
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Dermatology and Therapy|May 9, 2024
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 AnalysisLeon H Kircik, Linda Stein Gold, Michael Gold, et al.
Italian Journal of Pediatrics|March 4, 2016
Consensus Conference on Clinical Management of pediatric Atopic DermatitisElena Galli, Iria Neri, Giampaolo Ricci, et al.
Pediatric Dermatology|January 17, 2020
Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter databaseLeila H Shayegan, Laura E Levin, Eloise R Galligan, et al.
Pediatric Dermatology|November 28, 2020
Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes databaseLaura E Levin, Leila H Shayegan, Anne W Lucky, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
The Journal of Pediatrics|May 20, 2019
Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young AdultsJennifer T Huang, Carrie C Coughlin, Elena B Hawryluk, et al.
Journal of the American Academy of Dermatology|September 30, 2014
Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approachesRobert Sidbury, Wynnis L Tom, James N Bergman, et al.
Pageof 38

Showing results (341-350 of 377) with videos related to

Sort By:
Pageof 38
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Dermatology and Therapy|May 9, 2024
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 AnalysisLeon H Kircik, Linda Stein Gold, Michael Gold, et al.
Italian Journal of Pediatrics|March 4, 2016
Consensus Conference on Clinical Management of pediatric Atopic DermatitisElena Galli, Iria Neri, Giampaolo Ricci, et al.
Pediatric Dermatology|January 17, 2020
Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter databaseLeila H Shayegan, Laura E Levin, Eloise R Galligan, et al.
Pediatric Dermatology|November 28, 2020
Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes databaseLaura E Levin, Leila H Shayegan, Anne W Lucky, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
The Journal of Pediatrics|May 20, 2019
Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young AdultsJennifer T Huang, Carrie C Coughlin, Elena B Hawryluk, et al.
Journal of the American Academy of Dermatology|September 30, 2014
Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approachesRobert Sidbury, Wynnis L Tom, James N Bergman, et al.
Pageof 38